scholarly article | Q13442814 |
P819 | ADS bibcode | 2015PLoSO..1040136K |
P356 | DOI | 10.1371/JOURNAL.PONE.0140136 |
P932 | PMC publication ID | 4601692 |
P698 | PubMed publication ID | 26457809 |
P5875 | ResearchGate publication ID | 282812384 |
P50 | author | Zsuzsanna Jakab | Q4024870 |
P2093 | author name string | Viktória Nagy | |
András Gézsi | |||
Csaba Szalai | |||
Dániel J Erdélyi | |||
Katalin Csordás | |||
Nóra Kutszegi | |||
Orsolya Lautner-Csorba | |||
Gábor T Kovács | |||
Ágnes F Semsei | |||
Judit C Sági | |||
Krisztina Míta Gábor | |||
P2860 | cites work | Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia | Q73589836 |
[Importance of the National Childhood Cancer Registry in the field of paediatric oncology care in Hungary] | Q87811869 | ||
Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 | ||
Intron sequence directs RNA editing of the glutamate receptor subunit GluR2 coding sequence | Q24563210 | ||
Human T cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migration | Q28189515 | ||
Characterization of ionotropic glutamate receptors in human lymphocytes | Q28343936 | ||
Use of ?-asparaginase in childhood ALL | Q29041017 | ||
Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity | Q34400003 | ||
L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase | Q34400424 | ||
Genomic variants in exons and introns: identifying the splicing spoilers | Q35787564 | ||
Genome-wide analysis links NFATC2 with asparaginase hypersensitivity | Q35820373 | ||
Pharmacogenetics of glutamate system genes and SSRI-associated sexual dysfunction | Q36279178 | ||
Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. | Q36608593 | ||
Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia | Q36918761 | ||
The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization | Q37770689 | ||
Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults | Q38079075 | ||
Optimizing asparaginase therapy for acute lymphoblastic leukemia | Q38079114 | ||
The neurotransmitter glutamate and human T cells: glutamate receptors and glutamate-induced direct and potent effects on normal human T cells, cancerous human leukemia and lymphoma T cells, and autoimmune human T cells | Q38192495 | ||
Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia. | Q38248280 | ||
Asparaginase in acute lymphoblastic leukemia | Q38285254 | ||
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. | Q39835436 | ||
Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCISproject): an epidemiological study | Q44002855 | ||
Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia | Q45261834 | ||
Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. | Q46241489 | ||
Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial | Q46355327 | ||
Glutamate AMPA receptor subunit 1 gene (GRIA1) and DSM-IV-TR schizophrenia: a pilot case-control association study in an Italian sample | Q46982053 | ||
A direct approach to false discovery rates | Q56622258 | ||
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia | Q56999328 | ||
Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy | Q59662755 | ||
In interaction with gender a common CYP3A4 polymorphism may influence the survival rate of chemotherapy for childhood acute lymphoblastic leukemia | Q60054990 | ||
Glutamate Released by Dendritic Cells as a Novel Modulator of T Cell Activation | Q62399771 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 10 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | leukemia | Q29496 |
P304 | page(s) | e0140136 | |
P577 | publication date | 2015-10-12 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Subgroups of Paediatric Acute Lymphoblastic Leukaemia Might Differ Significantly in Genetic Predisposition to Asparaginase Hypersensitivity | |
P478 | volume | 10 |
Q38735393 | HLA-DRB1*07:01-HLA-DQA1*02:01-HLA-DQB1*02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemia |
Q64269386 | Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity |
Q38895172 | Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia |
Q64077129 | Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment |
Q38688039 | Pharmacogenomics in pediatric acute lymphoblastic leukemia: promises and limitations |
Q92542001 | Precision Medicine in Lymphoma by Innovative Instrumental Platforms |
Q48331843 | Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients. |
Search more.